NodThera
PrivateLast Round
IPO
Mar 27, 2026
Total Funding Raised
$145M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
NodThera is a biotechnology company that develops small molecule NLRP3 inflammasome inhibitors for the treatment of chronic inflammatory, cardiometabolic, and neuroinflammatory diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
NodThera Comparables
Compare NodThera with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Halia Therapeutics | 91% | |
| Ventus Therapeutics | 88% | |
| Eli Lilly and Company | 86% | |
NodThera Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | Mar 27, 2026 | ||||
| Series D | Apr 1, 2025 | ||||
| Series B | Jun 3, 2020 | ||||
| Series A | Jun 25, 2018 | ||||
| Seed | Jul 28, 2016 |
Key People
Founding team and executive leadership
NodThera Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Epidarex Capital | Series D, Series A, Series B, Seed |
| F-Prime Capital | Series D, Series A, Series B |
| TD Securities | Series B |
| Blue Owl Capital | Series D, Series B |
| 5AM Ventures | Series D, Series B, Series A |
| Novo Holdings | Series D, Series B |
| Sanofi Ventures | Series D, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 21, 2026
Clinical and commercial plan for ruvonoflast includes Phase 2 data in July 2026 and launch in early 2029.
- Mar 27, 2026
Completed an IPO round of funding.
NodThera Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about NodThera's valuation, stock price, and market status.